Jefferies Group reissued their buy rating on shares of Indivior (LON:INDV) in a research report sent to investors on Wednesday morning. They currently have a GBX 500 ($6.78) price target on the specialty pharmaceutical company’s stock.
Several other equities analysts have also recently commented on INDV. Royal Bank of Canada restated an outperform rating and issued a GBX 500 ($6.78) target price on shares of Indivior in a research report on Friday, December 1st. Morgan Stanley restated an equal weight rating and issued a GBX 410 ($5.56) target price on shares of Indivior in a research report on Friday, December 1st. Citigroup restated a neutral rating and issued a GBX 280 ($3.80) target price on shares of Indivior in a research report on Thursday, October 26th. Finally, Numis Securities restated a buy rating and issued a GBX 640 ($8.68) target price on shares of Indivior in a research report on Thursday, November 30th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of GBX 476.43 ($6.46).
Indivior (INDV) opened at GBX 401 ($5.44) on Wednesday. The company has a market cap of $2,890.00 and a P/E ratio of 1,542.31. Indivior has a 12-month low of GBX 246.50 ($3.34) and a 12-month high of GBX 421.50 ($5.72).
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.